Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
Although hepatic vein pressure gradient measurement is an accurate method for evaluation of portal HTN, this technique is invasive and not widely available.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
Among women giving birth, the rates of HCV infection increased more than 400% from 2000 to 2015, with rates much higher among those with opioid use disorder.
Two studies on hepatitis A and hepatitis B vaccination highlight opportunities to improve coverage of ≥2 doses of hepatitis A vaccine in children and hepatitis B vaccine series completion in adults.
Hepatitis E seropositivity is higher in older adults and may represent an increased exposure risk over time; in contrast, the opioid crisis has caused a demographic shift in hepatitis C infection, which is now a predominately millennial disease.
Direct-acting antiviral agents for treatment of hepatitis C virus may have higher sustained virologic responses in people coinfected with hepatitis B and hepatitis C viruses.
When treating hepatitis E virus, the addition of sofosbuvir to a ribavirin-based regimen in solid organ transplant recipients does not result in sustained virologic response.
Updated recommendations were presented for the prevention, diagnosis, treatment, and management of HCV infection in adults with chronic kidney disease.
The FDA is warning healthcare professionals that cases of liver decompensation, including liver failure and death, have been linked to certain hepatitis C drugs.
Direct-acting antiviral therapy may be a beneficial therapy for patients infected with HCV with a history of hepatocellular carcinoma by increasing overall survival.
The FDA has granted Breakthrough Therapy designation to peginterferon lambda (Lambda; Eiger BioPharmaceuticals) for the treatment of hepatitis delta virus (HDV) infection.
The development of Guillain-Barre syndrome (GBS) has demonstrated an association with existing hepatitis C virus (HCV) infection and mixed cryoglobulinemia, according to a case study published in BMC Infectious Diseases. The subtype severe acute motor sensory axonal neuropathy was classified as a subtype of GBS through electromyography, associated with severe clinical presentation. Researchers noted that only…
Data published in Clinical Infectious Diseases revealed that by 2014, less than one-third of individuals aged 18 to 49 years who were at risk for hepatitis B virus (HBV) exhibited hepatitis B surface antibody levels indicative of protection (anti-HBs >10 mIU/mL). Data from the 2003 to 2014 National Health and Nutrition Examination Surveys were used…
The United States Preventative Service Task Force has issued a statement that reaffirms its 2009 recommendations for screening pregnant women for hepatitis B virus.
The Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has voted to recommend that pediatric patients (2 to 18 years old) who have not previously received hepatitis A vaccine be routinely vaccinated at any age. Currently, the CDC recommends routine hepatitis A vaccination for children 12 to 23 months of…
Direct-acting antiviral (DAA) exposure may not be associated with higher rates of any serious adverse events when used for hepatitis C virus (HCV) treatment, according to a study published in JAMA Network Open. At this time, there are approximately 2.4 million individuals living in the United States who are infected with HCV. Further, 28% of…
Investigators sought to determine the risk for Parkinson disease development in patients with hepatitis C virus who received antiviral treatment and in patients who did not receive this treatment.
